A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia

作者：Advani Anjali S^*; Tiu Ramon; Saunthararajah Yogen; Maciejewski Jaroslaw; Copelan Edward A; Sobecks Ronald; Sekeres Mikkael A; Bates Jennifer; Rush Mary Lynn; Tripp Barbara; Salvado August; Noon Elysa; Howard Matthew; Jin Tao; Hsi Eric; Egorin Merrill J; Lim Kathleen; Cotta Claudiu V; Price Courtney; Kalaycio Matt

来源：Leukemia Research, 2010, 34(12): 1622-1626.

DOI：10.1016/j.leukres.2010.03.021

• Acute myeloid leukemia
• Relapse
• Treatment
• c-Kit
• Imatinib mesylate
• STAT5

The c-kit receptor is expressed in 95% of relapsed acute myeloid leukemias (AMLs) and mediates leukemic proliferation. We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7 + 3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design. Phosphorylated STAT5 was absent to minimally present in residual blasts on day 14 bone marrows. The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective.

• 出版日期2010-12